Regeneron, Bayer lose bid to block Sandoz from launching Eylea biosimilar

Intellectual Property 2025-09-08 11:55 pm By Cindy Cameronne | Sydney

Please login to bookmark

Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au